Spero Therapeutics (NASDAQ:SPRO) Bolsa

SPERO THERAPEUTICS INC

Spero Therapeutics

Spero Therapeutics Inc is a clinical-stage biopharmaceutical firm. It focuses on identifying, developing, and commercializing novel treatments for MDR (Multi-drug-resistant) bacterial infections and rare diseases. The company's product candidate, tebipenem pivoxil hydrobromide or tebipenem HBr, is designed to be an oral carbapenem-class antibiotic for use in adults to treat MDR Gram-negative infections. It is also developing SPR720, a novel oral antibiotic designed for the treatment of a rare, orphan disease caused by pulmonary non-tuberculous mycobacterial infections, or NTM disease. Besides, it is also focused on SPR206, a next-generation polymyxin investigational product candidate being developed as an IV-administered medicine to treat MDR Gram-negative infections in the hospital.

Spero Therapeutics Inc

Sprott Active Gold & Silver Miners ETF

Sprott Copper Miners ETF

Sprott Critical Materials ETF

Sprott Focus Trust, Inc. - Closed End Fund

Sprott Focus Trust Inc

Sprott Gold Miners ETF

Sprott Inc

Sprott Junior Copper Miners ETF

Sprott Junior Gold Miners ETF

Sprott Junior Uranium Miners ETF

Sprott Lithium Miners ETF

Sprott Nickel Miners ETF

Sprott Physical Gold Trust

Sprott Physical Gold and Silver Trust Units

Sprott Physical Gold and Silver Trust

Sprott Physical Platinum and Palladium Trust

Sprott Physical Platinum & Palladium Tr

Sprott Physical Silver Trust

Sprott Physical Uranium Trust

Sprott Silver Miners & Physical Silver ETF

Sprott Uranium Miners ETF

Sprout AI Inc

Sprout Social, Inc - Class A Common Stock

Sprout Social Inc

SPROUT TINY HOMES by Sprout Tiny Homes, Inc.

Sprout Tiny Homes Inc

Sproutly Canada Inc

Sprouts Farmers Market, Inc. - Common Stock

Sprouts Farmers Market Inc

During times of turbulence and uncertainty in the markets, many investors turn to dividend-yielding stocks. These are often companies that have high free cash flows and reward shareholders with a<a href="https://www.benzinga.com/yield-investments"> high dividend payout</a>.
Benzinga readers can review the latest analyst takes on their favorite stocks by visiting <a href="https://www.benzinga.com/analyst-stock-ratings">Analyst Stock Ratings</a> page. Traders can sort through Benzinga's extensive database of analyst ratings, including <a href="https://www.benzinga.com/analyst-ratings/analyst-color/22/09/28888638/exclusive-study-finds-benzinga-analyst-ratings-data-yields-market-beating-strategie">by analyst accuracy</a>.
Below are the ratings of the most accurate analysts for three high-yielding stocks in the health care sector.
<h3 class="wp-block-heading">Pfizer Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PFE#NYSE">PFE</a>)</h3>
<ul class="wp-block-list">
<li>Dividend Yield: 7.37%</li>
<li>UBS analyst Trung Huynh maintained a Neutral rating and raised the price target from $24 to $25 on April 30, 2025. This analyst has an accuracy rate of 70%.</li>
<li>Guggenheim analyst Vamil Divan reiterated a Buy rating on March 18, 2025. This analyst has an accuracy rate of 74%.</li>
<li>Recent News: Arvinas, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARVN#NASDAQ">ARVN</a>) on Friday announced in a press release the submission of a New Drug Application to the U.S. Food and Drug Administration (FDA) with its partner Pfizer.</li>
<li>Benzinga Pro&#8217;s real-time newsfeed alerted to <a href="https://www.benzinga.com/pro/register?utm_adType=bzprocontent&amp;utm_campaign=14daytrial&amp;utm_ad=0609">latest PFE news</a>. </li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="https://www.benzinga.com/pro/register?utm_adType=bzprocontent&amp;utm_campaign=14daytrial&amp;utm_ad=0609"><img loading="lazy" decoding="async" width="882" height="842" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/09091603/image-114.png" alt="" class="wp-image-943187" style="width:620px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/09091603/image-114.png 882w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/09091603/image-114-300x286.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/09091603/image-114-768x733.png 768w" sizes="(max-width: 882px) 100vw, 882px" /></a></figure>
<h3 class="wp-block-heading">Merck &amp; Co., Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MRK#NYSE">MRK</a>)</h3>
<ul class="wp-block-list">
<li>Dividend Yield: 4.10%</li>
<li>Citigroup analyst Andrew Baum downgraded the stock from Buy to Neutral and cut the price target from $115 to $84 on May 14, 2025. This analyst has an accuracy rate of 69%.</li>
<li>Guggenheim analyst Vamil Divan reiterated a Buy rating with a price target of $115 on April 17, 2025. This analyst has an accuracy rate of 74%.</li>
<li>Recent News: On Monday, Merck reported positive topline results from the first two Phase 3 CORALreef trials evaluating enlicitide decanoate for the treatment of adults with hyperlipidemia.</li>
<li>Benzinga Pro's real-time newsfeed alerted to latest MRK <a href="https://www.benzinga.com/pro/register?utm_adType=bzprocontent&amp;utm_campaign=14daytrial&amp;utm_ad=0609">news </a></li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="https://www.benzinga.com/pro/register?utm_adType=bzprocontent&amp;utm_campaign=14daytrial&amp;utm_ad=0609"><img loading="lazy" decoding="async" width="857" height="832" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/09091645/image-115.png" alt="" class="wp-image-943188" style="width:582px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/09091645/image-115.png 857w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/09091645/image-115-300x291.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/09091645/image-115-768x746.png 768w" sizes="(max-width: 857px) 100vw, 857px" /></a></figure>
<h3 class="wp-block-heading">GSK plc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GSK#NYSE">GSK</a>)</h3>
<ul class="wp-block-list">
<li>Dividend Yield: 3.88%</li>
<li>Oppenheimer analyst Rupesh Parikh maintained an Outperform rating and raised the price target from $87 to $93 on Feb. 13, 2025. This analyst has an accuracy rate of 72%.</li>
<li>Canaccord Genuity analyst Susan Anderson maintained a Buy rating and increased the price target from $93 to $100 on Feb. 7, 2025. This analyst has an accuracy rate of 67%.</li>
<li>Recent News: GSK and Spero Therapeutics Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SPRO#NASDAQ">SPRO</a>), on May 28, announced that the pivotal phase 3 PIVOT-PO trial evaluating tebipenem HBr for complicated urinary tract infections (cUTIs) will stop early for efficacy.</li>
<li>Benzinga Pro&#8217;s real-time newsfeed alerted to latest GSK <a href="https://www.benzinga.com/pro/register?utm_adType=bzprocontent&amp;utm_campaign=14daytrial&amp;utm_ad=0609">news </a></li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="https://www.benzinga.com/pro/register?utm_adType=bzprocontent&amp;utm_campaign=14daytrial&amp;utm_ad=0609"><img loading="lazy" decoding="async" width="863" height="838" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/09091720/image-116.png" alt="" class="wp-image-943189" style="width:552px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/09091720/image-116.png 863w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/09091720/image-116-300x291.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/09091720/image-116-768x746.png 768w" sizes="(max-width: 863px) 100vw, 863px" /></a></figure>
<figure class="wp-block-embed is-type-video is-provider-youtube wp-block-embed-youtube wp-embed-aspect-16-9 wp-has-aspect-ratio"> 
<div class="wp-block-embed__wrapper">
<iframe loading="lazy" title="How to Find Dividend Stocks: Scan, Analyze, and Capture with Benzinga Pro" width="500" height="281" src="https://www.youtube.com/embed/pVF0O2lsEH4?start=1&#038;feature=oembed" frameborder="0" allow="accelerometer; autoplay; clipboard-write; encrypted-media; gyroscope; picture-in-picture; web-share" referrerpolicy="strict-origin-when-cross-origin" allowfullscreen></iframe>
</div>
</figure>
Read More: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/trading-ideas/long-ideas/25/06/45811726/cramer-says-hes-not-going-to-really-want-to-do-a-lot-of-china-right-now">Cramer Says He&#8217;s &#8216;Not Going To Really Want To Do A Lot Of China Right Now&#8217;</a> </li>
</ul>
Photo via Shutterstock

Long Ideas

News

Dividends

Price Target

Pre-Market Outlook

Markets

Analyst Ratings

Trading Ideas

ARVN

SPRO

Wall Street's Most Accurate Analysts Spotlight On 3 Health Care Stocks Delivering High-Dividend Yields

Benzinga examined the prospects for <a href="http://www.benzinga.com/trading-ideas" target="_blank" rel="noreferrer noopener">many investors' favorite stocks</a> over the last week — here's a look at some of our top stories.
In May, U.S. stocks recorded their strongest monthly rally since November 2023, driven by easing trade tensions and robust tech earnings. The S&amp;P 500 rose 6.2%, and the Nasdaq Composite surged 9.6%, returning both indices to positive territory for the year. The "Magnificent Seven" tech giants led the charge, with Nvidia (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>) stock climbing 24% after reporting a 70% year-over-year revenue increase.
Despite the tech sector's dominance, investors anticipate a broader market rally, citing improving earnings in sectors like industrials, consumer staples, and financials. Analysts expect the earnings growth gap between the Magnificent Seven and the rest of the S&amp;P 500 to narrow in 2025.
However, uncertainties remain. A U.S. court ruling declared President Donald Trump's recent tariffs illegal, though the decision was promptly appealed. Analysts warn that renewed tariffs, particularly on chips and pharmaceuticals, could threaten the sustainability of recent market gains.
Benzinga provides daily reports on the stocks most popular with investors. Here are a few of this past week's most bullish and bearish posts that are worth another look.

The Bulls
<a href="https://www.benzinga.com/analyst-ratings/analyst-color/25/05/45655507/tech-analyst-expects-palantir-stock-to-rise-above-400-as-ai-revolution-kicks-into-gear">"Tech analyst expects Palantir stock to rise above $400 as AI revolution kicks into gear"</a>, by Adam Eckert, reports that Wedbush analyst Dan Ives predicts Palantir Technologies Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PLTR#NYSE">PLTR</a>) will surpass $400 per share and reach a $1 trillion market cap within a few years, citing its leadership in AI and calling it the "Messi of AI."
<a href="https://www.benzinga.com/analyst-ratings/analyst-color/25/05/45675006/nvidia-stock-has-significant-upside-as-ai-godfather-jensen-huang-delivers-another-robust-quarter">"Nvidia stock has ‘significant upside' as AI ‘godfather' Jensen Huang delivers another ‘robust quarter'"</a>, by Chris Katje, reports that Nvidia Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>) shares rose after the company beat Q1 estimates and analysts projected a market cap of up to $5 trillion, citing surging demand for its Blackwell AI chips and growth in AI infrastructure despite China export restrictions.
<a href="https://www.benzinga.com/news/earnings/25/05/45682895/ulta-beauty-stock-climbs-after-better-than-expected-q1-report-raised-fiscal-2025-outlook">"Ulta Beauty stock climbs after better-than-expected Q1 report, raised fiscal 2025 outlook"</a>, by Erica Kollmann, reports that Ulta Beauty Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ULTA#NASDAQ">ULTA</a>) shares surged over 11% after the company exceeded Q1 earnings and revenue expectations, posting $6.70 EPS and $2.85 billion in sales, and raised its fiscal 2025 guidance amid strong demand for skincare and fragrance products.
For additional bullish calls of the past week, check out the following:
<a href="https://www.benzinga.com/news/earnings/25/05/45683235/uipath-stock-surges-on-q1-earnings-beat-raised-guidance-this-was-a-milestone-quarter">UiPath Stock Surges On Q1 Earnings Beat, Raised Guidance: ‘This Was A Milestone Quarter'</a>
<a href="https://www.benzinga.com/government/regulations/25/05/45650179/uranium-stocks-hit-17-year-highs-as-mays-rally-marks-best-month-on-record">Uranium Stocks Hit 17-Year Highs As May's Rally Marks Best Month On Record</a>
<a href="https://www.benzinga.com/general/biotech/25/05/45648350/why-is-gsk-partner-spero-therapeutics-stock-skyrocketing-on-wednesday">Why Is GSK Partner Spero Therapeutics Stock Skyrocketing On Wednesday?</a>

The Bears
<a href="https://www.benzinga.com/news/earnings/25/05/45681892/marvell-technology-stock-slips-after-q1-results-details">"Marvell Technology stock slips after Q1 results: Details"</a>, by Erica Kollmann, reports that Marvell Technology Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRVL#NASDAQ">MRVL</a>) shares fell over 3% after the company posted Q1 adjusted earnings of 62 cents per share on $1.9 billion in revenue—both slightly above analyst estimates—but investors showed muted enthusiasm despite strong AI-driven data center demand and a raised Q2 revenue forecast of $2 billion.
<a href="https://www.benzinga.com/trading-ideas/movers/25/05/45692578/regeneron-sanofi-stock-falls-after-uneven-smokers-lung-drug-data">"Regeneron, Sanofi stock falls after uneven smoker's lung drug data"</a>, by Vandana Singh, reports that Regeneron Pharmaceuticals Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/REGN#NASDAQ">REGN</a>) and Sanofi SA (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNY#NASDAQ">SNY</a>) shares declined after their experimental COPD drug, itepekimab, showed a 27% reduction in exacerbations in one Phase 3 trial but failed to meet the primary endpoint in a second trial, raising concerns about its efficacy.
<a href="https://www.benzinga.com/economics/macro-economic-events/25/05/45645056/gold-etf-bleeds-money-at-fastest-pace-in-3-years-is-the-safe-haven-trade-over">"Gold ETF bleeds money at fastest pace in 3 years — is the safe-haven trade over?"</a>, by Piero Cingari, reports that the SPDR Gold Shares ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GLD#NYSE">GLD</a>) experienced $2.1 billion in outflows in May — its worst since July 2022 — as easing U.S.-China tensions and a surging S&amp;P 500 shifted investor appetite toward riskier assets, though Goldman Sachs still forecasts gold reaching $3,700 per ounce by year-end, driven by central bank demand and long-term macro risks.
For more bearish takes, be sure to see these posts:
<a href="https://www.benzinga.com/news/stock-split/25/05/45679654/mullen-automotive-stock-is-tumbling-thursday-whats-driving-the-action">Mullen Automotive Stock Is Tumbling Thursday: What's Driving The Action?</a>
<a href="https://www.benzinga.com/general/biotech/25/05/45655674/rocket-pharmas-gene-therapy-future-clouded-by-regulatory-uncertainty">Rocket Pharma's Gene Therapy Future Clouded By Regulatory Uncertainty</a>
<a href="https://www.benzinga.com/general/biotech/25/05/45624650/why-is-neuropace-stock-falling-after-epilepsy-treatment-study-data">Why Is NeuroPace Stock Falling After Epilepsy Treatment Study Data?</a>
Keep up with all the latest breaking news and trading ideas by following <a href="https://twitter.com/Benzinga" target="_blank" rel="noreferrer noopener">Benzinga</a><a href="http://twitter.com/Benzinga" target="_blank" rel="noreferrer noopener"> on X</a>.
Image created using artificial intelligence via Midjourney.

MRVL

MULN

NPCE

NVDA

PATH

PLTR

RCKT

REGN

ULTA

Benzinga Bulls And Bears: Nvidia, Palantir, Marvell Technology — And Markets Rallied In May

<h3>Gainers</h3>
<ul>
<li>Basel Medical Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BMGL#NASDAQ">BMGL</a>) shares rose 171.6% to $2.83 during Friday's regular session. The market value of their outstanding shares is at $53.0 million. </li>
<li>BioLine Rx (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BLRX#NASDAQ">BLRX</a>) stock moved upwards by 50.92% to $5.72. The market value of their outstanding shares is at $21.2 million. The company's, Q1 earnings came out 3 days ago. </li>
<li>Imunon (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IMNN#NASDAQ">IMNN</a>) shares moved upwards by 39.78% to $2.78. The company's market cap stands at $48.7 million. </li>
<li>Regencell Bioscience (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RGC#NASDAQ">RGC</a>) stock moved upwards by 23.48% to $915.0. The company's market cap stands at $11.9 billion. </li>
<li>Spero Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SPRO#NASDAQ">SPRO</a>) shares rose 23.0% to $2.62. The company's market cap stands at $146.4 million. </li>
<li>Inspire Veterinary (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IVP#NASDAQ">IVP</a>) shares rose 20.47% to $1.74. The market value of their outstanding shares is at $3.7 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>CollPlant Biotechnologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CLGN#NASDAQ">CLGN</a>) stock fell 29.5% to $3.2 during Friday's regular session. The market value of their outstanding shares is at $36.6 million. As per the news, the Q1 earnings report came out 2 days ago. </li>
<li>Summit Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMMT#NASDAQ">SMMT</a>) shares declined by 29.48% to $18.48. The market value of their outstanding shares is at $13.7 billion. </li>
<li>Alzamend Neuro (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALZN#NASDAQ">ALZN</a>) stock fell 28.41% to $3.9. The market value of their outstanding shares is at $2.8 million. </li>
<li>Harvard Bioscience (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HBIO#NASDAQ">HBIO</a>) shares decreased by 27.38% to $0.49. The market value of their outstanding shares is at $21.5 million. </li>
<li>Aspire Biopharma Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ASBP#NASDAQ">ASBP</a>) stock declined by 24.29% to $0.46. The market value of their outstanding shares is at $22.5 million. </li>
<li>EXoZymes (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EXOZ#NASDAQ">EXOZ</a>) shares decreased by 21.01% to $10.98. The company's market cap stands at $91.8 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Movers

ALZN

ASBP

BLRX

BMGL

CLGN

EXOZ

HBIO

IMNN

SMMT

12 Health Care Stocks Moving In Friday's Intraday Session

<h3>Gainers</h3>
<ul>
<li>Aspire Biopharma Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ASBP#NASDAQ">ASBP</a>) stock increased by 39.5% to $0.99 during Wednesday's after-market session. The market value of their outstanding shares is at $48.8 million. </li>
<li>ORIC Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ORIC#NASDAQ">ORIC</a>) shares rose 17.92% to $7.04. The company's market cap stands at $500.4 million. </li>
<li>NanoVibronix (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NAOV#NASDAQ">NAOV</a>) stock increased by 16.87% to $1.0. </li>
<li>Veeva Systems (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VEEV#NYSE">VEEV</a>) shares moved upwards by 16.44% to $273.06. The market value of their outstanding shares is at $44.4 billion. As per the press release, Q1 earnings came out today. </li>
<li>Taysha Gene Therapies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSHA#NASDAQ">TSHA</a>) shares moved upwards by 14.75% to $2.8. The market value of their outstanding shares is at $601.0 million. </li>
<li>Indaptus Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INDP#NASDAQ">INDP</a>) shares rose 13.17% to $0.36. The company's market cap stands at $5.7 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Immunic (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IMUX#NASDAQ">IMUX</a>) stock fell 13.6% to $0.8 during Wednesday's after-market session. The company's market cap stands at $76.6 million. </li>
<li>bioAffinity Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BIAF#NASDAQ">BIAF</a>) shares decreased by 12.48% to $0.35. The market value of their outstanding shares is at $9.5 million. </li>
<li>Intellia Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NTLA#NASDAQ">NTLA</a>) shares fell 11.5% to $8.55. The company's market cap stands at $885.6 million. </li>
<li>Klotho Neurosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KLTO#NASDAQ">KLTO</a>) shares decreased by 9.53% to $0.19. The company's market cap stands at $6.1 million. </li>
<li>Spero Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SPRO#NASDAQ">SPRO</a>) stock decreased by 8.09% to $2.16. The market value of their outstanding shares is at $120.7 million. </li>
<li>Abpro Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ABP#NASDAQ">ABP</a>) shares decreased by 7.88% to $0.24. The market value of their outstanding shares is at $14.3 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

BIAF

IMUX

INDP

KLTO

NAOV

NTLA

ORIC

TSHA

VEEV

12 Health Care Stocks Moving In Wednesday's After-Market Session

<h3>Gainers</h3>
<ul>
<li>Spero Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SPRO#NASDAQ">SPRO</a>) shares moved upwards by 203.7% to $2.07 during Wednesday's regular session. The market value of their outstanding shares is at $115.7 million. </li>
<li>Aspire Biopharma Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ASBP#NASDAQ">ASBP</a>) stock rose 156.84% to $0.61. The market value of their outstanding shares is at $30.2 million. </li>
<li>CollPlant Biotechnologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CLGN#NASDAQ">CLGN</a>) stock increased by 40.41% to $2.71. The market value of their outstanding shares is at $31.0 million. As per the press release, Q1 earnings came out today. </li>
<li>bioAffinity Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BIAF#NASDAQ">BIAF</a>) stock moved upwards by 22.24% to $0.33. The company's market cap stands at $9.0 million. </li>
<li>ITeos Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ITOS#NASDAQ">ITOS</a>) shares rose 21.86% to $10.39. The company's market cap stands at $397.8 million. </li>
<li>WORK Medical Tech Gr (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WOK#NASDAQ">WOK</a>) stock moved upwards by 21.71% to $0.97. The company's market cap stands at $14.1 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Oragenics (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/OGEN#AMEX">OGEN</a>) shares fell 28.9% to $0.14 during Wednesday's regular session. The market value of their outstanding shares is at $2.9 million. </li>
<li>Tempus AI (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TEM#NASDAQ">TEM</a>) shares declined by 17.92% to $54.07. The company's market cap stands at $9.3 billion. </li>
<li>Imunon (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IMNN#NASDAQ">IMNN</a>) stock fell 17.19% to $1.88. The market value of their outstanding shares is at $32.9 million. </li>
<li>SCWorx (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WORX#NASDAQ">WORX</a>) stock decreased by 15.45% to $0.57. The company's market cap stands at $2.0 million. </li>
<li>SS Innovations (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SSII#NASDAQ">SSII</a>) stock decreased by 14.91% to $6.03. The company's market cap stands at $1.1 billion. </li>
<li>Revelation Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/REVB#NASDAQ">REVB</a>) stock decreased by 13.67% to $1.96. The market value of their outstanding shares is at $1.8 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ITOS

OGEN

REVB

SSII

WORX

12 Health Care Stocks Moving In Wednesday's Intraday Session

U.S. stocks traded lower midway through trading, with the Dow Jones index falling around 100 points on Wednesday.
The Dow traded down 0.25% to 42,237.69 while the NASDAQ fell 0.07% to 19,186.35. The S&amp;P 500 also fell, dropping, 0.18% to 5,911.13.
Check This Out: <a href="https://www.benzinga.com/25/05/45640155/wall-streets-most-accurate-analysts-give-their-take-on-3-materials-stocks-delivering-high-dividend-yields-5">Wall Street&#8217;s Most Accurate Analysts Give Their Take On 3 Materials Stocks Delivering High-Dividend Yields</a>
Leading and Lagging Sectors Communication services shares jumped by 0.5% on Wednesday.
In trading on Wednesday, materials stocks fell by 0.5%.
Top Headline
Macy's Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/M#NYSE">M</a>) on Wednesday revised its annual outlook on initial and current tariffs, some moderation in consumer discretionary spending, and a heightened competitive promotional landscape.
Macy's lowered fiscal 2025 adjusted earnings per share from $2.05-$2.25 to $1.60-$2.00 compared to the consensus of $1.93. Still, the retail giant affirmed its 2025 sales guidance of $21 billion-$21.4 billion versus the consensus of $21.31 billion.
The retailer reported net sales of $4.6 billion for the first quarter of 2025, down 5.1% year over year, beating the consensus of $4.50 billion.
Equities Trading UP &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<ul class="wp-block-list">
<li>Signing Day Sports, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SGN#NYSE">SGN</a>) shares shot up 270% to $3.0705 after announcing a business combination agreement with BlockchAIn to acquire 100% of the company and form a crypto mining, AI, and high-performance computing data hosting company.</li>
<li>Shares of Spero Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SPRO#NASDAQ">SPRO</a>) got a boost, surging 205% to $2.0834 after the company and GSK announced the Phase 3 study of tebipenem HBr met its primary endpoint and will stop early for efficacy.</li>
<li>Monro, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MNRO#NASDAQ">MNRO</a>) shares were also up, gaining 35% to $17.23 after the company reported a fourth-quarter revenue beat and approved a first-quarter cash dividend of $0.28 per share. Additionally, the company announced it has conducted a store portfolio review and has identified 145 underperforming locations for closure.</li>
</ul>
Equities Trading DOWN
<ul class="wp-block-list">
<li>InflaRx N.V. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IFRX#NASDAQ">IFRX</a>) shares dropped 59% to $0.7382 after the company halted Vilobelimab Phase 3 trial in pyoderma Gangrenosum after futility finding in interim analysis.</li>
<li>Shares of Cemtrex, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CETX#NASDAQ">CETX</a>) were down 47% to $0.8901 after the company announced a $1.25 million public offering.</li>
<li>Tempus AI, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TEM#NASDAQ">TEM</a>) was down, falling 16% to $55.28 after Spruce Point issued a &#8216;Strong Sell&#8217; opinion on the stock.</li>
</ul>
Commodities In commodity news, oil traded up 2.1% to $62.14 while gold traded up 0.1% at $3,303.10.
Silver traded down 0.1% to $33.275 on Wednesday, while copper fell 1.1% to $4.6880.
Euro zone
European shares were lower today. The eurozone's STOXX 600 fell 0.38%, while Spain's IBEX 35 Index fell 0.87%. London's FTSE 100 fell 0.28%, Germany's DAX 40 fell 0.43% and France's CAC 40 slipped 0.15% during the session.
Asia Pacific Markets
Asian markets closed lower on Wednesday, with Japan's Nikkei falling 0.005%, Hong Kong's Hang Seng Index dipping 0.53%, China's Shanghai Composite Index falling 0.02% and India's BSE Sensex falling 0.29%.
Economics
<ul class="wp-block-list">
<li>The volume of mortgage applications in the US declined by 1.2% from the previous week during the week ending May 23.</li>
<li>The composite manufacturing index in the US Fifth District rose to -9 in May compared to -13 in April.</li>
</ul>
Now Read This: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/25/05/45641430/jim-cramer-says-this-quantum-computing-stock-is-so-high-and-too-speculative">Jim Cramer Says This Quantum Computing Stock Is &#8216;So High&#8217; And &#8216;Too Speculative&#8217;</a> </li>
</ul>
Photo via Shutterstock

Earnings

Equities

Short Sellers

Eurozone

Commodities

Intraday Update

CETX

IFRX

MNRO

Crude Oil Gains 2%; Macy's Lowers Earnings Forecast

GSK plc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GSK#NYSE">GSK</a>) and Spero Therapeutics Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SPRO#NASDAQ">SPRO</a>) on Wednesday announced that the pivotal phase 3 PIVOT-PO trial evaluating tebipenem HBr for complicated urinary tract infections (cUTIs) will stop <a target="_blank" href="https://www.benzinga.com/general/health-care" rel="noreferrer noopener">early for efficacy</a>.&nbsp;
Spero&#8217;s stock price was up 245.89% at last check Wednesday following the news. 
The decision <a target="_blank" href="https://otp.tools.investis.com/generic/regulatory-story.aspx?cid=410&amp;newsid=1948433" rel="noreferrer noopener">follows</a> a recommendation from an Independent Data Monitoring Committee (IDMC) based on a planned interim analysis of data from 1,690 patients enrolled in the study.&nbsp;
Also Read: <a target="_blank" href="https://www.benzinga.com/general/biotech/25/05/45406673/gsk-to-buy-phase-3-ready-liver-disease-drug-for-up-to-2-billion" rel="noreferrer noopener">GSK To Buy Phase-3 Ready Liver Disease Drug For Up To $2 Billion</a>
If approved, tebipenem HBr would be the first oral carbapenem antibiotic&nbsp;for patients in the U.S. who suffer from cUTIs. It would add to&nbsp;GSK&#8217;s anti-infectives portfolio and help address the challenges of antimicrobial resistance (AMR).
The trial met the primary endpoint of non-inferiority&nbsp;of tebipenem HBr compared to intravenous imipenem-cilastatin in hospitalized adult patients with cUTI, including pyelonephritis,&nbsp;on the overall response (composite of clinical cure plus microbiological eradication) at the test-of-cure visit.&nbsp;
The IDMC review did not identify any new safety concerns beyond those reported in other studies with tebipenem. Diarrhea and headache are the two most reported adverse events. 
GSK plans to work with U.S. regulatory authorities to include the data in a filing in 2025.
GSK&#8217;s Chief Scientific Officer Tony Wood said there are limited oral options for drug-resistant infections. This contributes to over $6 billion per year in US healthcare costs.
&nbsp;An estimated 2.9 million cases of cUTIs are treated annually in the U.S. alone. The current standard of care includes carbapenem antibiotics, especially in case of sepsis and allergies or resistance to other antibiotics, but they are only available for IV administration.
Federal funds from the&nbsp;U.S.&nbsp;Department of Health and Human Services, the Administration for Strategic Preparedness and Response, and the Biomedical Advanced Research and Development Authority (BARDA) support the development of tebipenem HBr.
It is GSK&#8217;s second anti-infective program to be stopped early for efficacy in Phase 3, following the EAGLE 2 and EAGLE 3 trials for gepotidacin in 2022.
In March, the US Food and Drug Administration (FDA) approved&nbsp;GSK&#8217;s Blujepa&nbsp;(gepotidacin) for female adults (≥40 kg) and pediatric patients (≥12 years, ≥40 kg) with uncomplicated urinary&nbsp;<a target="_blank" href="https://www.benzinga.com/25/03/44496482/fda-approves-gsks-oral-antibiotic-for-urinary-tract-infections-for-females-aged-12-years-and-older" rel="noreferrer noopener">tract infections (uUTIs)</a>.
In September 2022, GSK entered into an exclusive license agreement with Spero Therapeutics to develop and commercialize tebipenem HBr in all markets except <a target="_blank" href="https://www.benzinga.com/general/biotech/22/09/28960518/spero-therapeutics-stock-almost-doubles-on-gsk-pact-for-its-lead-antibiotic" rel="noreferrer noopener">certain Asian territories</a>.&nbsp;
Price Action: GSK is down 0.33%, trading at around $39.32 per share. 
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/general/biotech/25/05/45629452/why-is-teva-stock-trading-higher-on-tuesday" target="_blank" rel="noreferrer noopener">Why Is Teva Stock Trading Higher On Tuesday?</a></li>
</ul>
Image: Shutterstock

Biotech

Large Cap

Health Care

General

Why Is GSK Partner Spero Therapeutics Stock Skyrocketing On Wednesday?

U.S. stocks traded higher this morning, with the Dow Jones index jumping around 100 points on Wednesday.
Following the market opening Wednesday, the Dow traded up 0.22% to 42,438.74 while the NASDAQ gained 0.19% to 19,235.41. The S&amp;P 500 also rose, gaining, 0.21% to 5,933.97.
Check This Out: <a href="https://www.benzinga.com/25/05/45640155/wall-streets-most-accurate-analysts-give-their-take-on-3-materials-stocks-delivering-high-dividend-yields-5">Wall Street&#8217;s Most Accurate Analysts Give Their Take On 3 Materials Stocks Delivering High-Dividend Yields</a>
Leading and Lagging Sectors Communication services shares jumped by 0.5% on Wednesday.
In trading on Wednesday, materials stocks fell by 0.5%.
Top Headline
Abercrombie &amp; Fitch Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ANF#NYSE">ANF</a>) reported better-than-expected first-quarter earnings on Wednesday.
The company posted adjusted EPS of $1.59, beating the street view of $1.40. Quarterly sales of $1.1 billion outpaced the analyst consensus estimate of $1.08 billion.
The company expects second-quarter net sales growth in the range of 3% to 5% and EPS of $2.10-$2.30 vs consensus of $2.53. Abercrombie &amp; Fitch revised FY25 guidance for net sales growth to 3% to 6% (from 3% to 5% prior) and EPS to $9.50 to $10.50 (from $10.40 to $11.40) vs. street view of $10.75.
Equities Trading UP &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<ul class="wp-block-list">
<li>Signing Day Sports, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SGN#NYSE">SGN</a>) shares shot up 301% to $3.3297 after announcing a business combination agreement with BlockchAIn to acquire 100% of the company and form a crypto mining, AI, and high-performance computing data hosting company.</li>
<li>Shares of Spero Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SPRO#NASDAQ">SPRO</a>) got a boost, surging 218% to $2.17 after the company and GSK announced the Phase 3 study of tebipenem HBr met its primary endpoint and will stop early for efficacy.</li>
<li>Safe &amp; Green Holdings Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SGBX#NASDAQ">SGBX</a>) shares were also up, gaining 117% to $1.20.</li>
</ul>
Equities Trading DOWN
<ul class="wp-block-list">
<li>InflaRx N.V. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IFRX#NASDAQ">IFRX</a>) shares dropped 59% to $0.7501 after the company halted Vilobelimab Phase 3 trial in pyoderma Gangrenosum after futility finding in interim analysis.</li>
<li>Shares of Cemtrex, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CETX#NASDAQ">CETX</a>) were down 46% to $0.9022 after the company announced a $1.25 million public offering.</li>
<li>ESS Tech, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GWH#NYSE">GWH</a>) was down, falling 41% to $1.1550.</li>
</ul>
Commodities In commodity news, oil traded up 1.4% to $61.74 while gold traded up 0.4% at $3,311.80.
Silver traded up 0.3% to $33.40 on Wednesday, while copper fell 0.5% to $4.7165.
Euro zone
European shares were lower today. The eurozone's STOXX 600 fell 0.3%, while Spain's IBEX 35 Index fell 0.8%. London's FTSE 100 fell 0.1%, Germany's DAX 40 fell 0.4% and France's CAC 40 slipped 0.1% during the session.
Asia Pacific Markets
Asian markets closed lower on Wednesday, with Japan's Nikkei falling 0.005%, Hong Kong's Hang Seng Index dipping 0.53%, China's Shanghai Composite Index falling 0.02% and India's BSE Sensex falling 0.29%.
Economics
The volume of mortgage applications in the US declined by 1.2% from the previous week during the week ending May 23.
Now Read This: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/25/05/45641430/jim-cramer-says-this-quantum-computing-stock-is-so-high-and-too-speculative">Jim Cramer Says This Quantum Computing Stock Is &#8216;So High&#8217; And &#8216;Too Speculative&#8217;</a> </li>
</ul>
Photo via Shutterstock

SGBX

US Stocks Gain; Abercrombie & Fitch Posts Upbeat Earnings

Spero Therapeutics Shares Halted On Circuit Breaker To The Upside, Stock Now Up 228.4%

<h3>Gainers</h3>
<ul>
<li>Spero Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SPRO#NASDAQ">SPRO</a>) shares increased by 237.2% to $2.3 during Wednesday's pre-market session. The market value of their outstanding shares is at $128.5 million. </li>
<li>Aspire Biopharma Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ASBP#NASDAQ">ASBP</a>) stock moved upwards by 18.44% to $0.28. The company's market cap stands at $13.9 million. </li>
<li>Veru (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VERU#NASDAQ">VERU</a>) shares rose 15.91% to $0.59. The market value of their outstanding shares is at $86.4 million. </li>
<li>Revelation Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/REVB#NASDAQ">REVB</a>) shares increased by 12.77% to $2.56. The market value of their outstanding shares is at $2.4 million. </li>
<li>Maze Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MAZE#NASDAQ">MAZE</a>) stock increased by 9.37% to $12.25. The company's market cap stands at $536.5 million. </li>
<li>Aclaris Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACRS#NASDAQ">ACRS</a>) shares increased by 8.66% to $1.38. The company's market cap stands at $149.4 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Imunon (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IMNN#NASDAQ">IMNN</a>) stock decreased by 30.4% to $1.58 during Wednesday's pre-market session. The company's market cap stands at $27.7 million. </li>
<li>Sonnet BioTherapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SONN#NASDAQ">SONN</a>) stock fell 16.47% to $0.99. The market value of their outstanding shares is at $3.1 million. </li>
<li>SCWorx (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WORX#NASDAQ">WORX</a>) shares fell 13.95% to $0.59. The market value of their outstanding shares is at $2.1 million. </li>
<li>NewGenIvf Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NIVF#NASDAQ">NIVF</a>) stock fell 11.75% to $2.33. The market value of their outstanding shares is at $1.7 million. </li>
<li>Regencell Bioscience (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RGC#NASDAQ">RGC</a>) shares declined by 10.86% to $447.17. The market value of their outstanding shares is at $5.8 billion. </li>
<li>Senti Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNTI#NASDAQ">SNTI</a>) stock decreased by 7.86% to $3.05. The company's market cap stands at $79.5 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ACRS

MAZE

NIVF

SNTI

SONN

VERU

12 Health Care Stocks Moving In Wednesday's Pre-Market Session

OKTA: -13% &#x7C; <a href="https://www.benzinga.com//node/45630649">Okta shares are trading lower following the company's Q1 earnings report. In its outlook, the company said it is now factoring in potential risks related to the uncertain economic environment for the remainder of FY26.</a>
&nbsp;
MTN: 12% &#x7C; <a href="https://www.benzinga.com//node/45631212">Vail Resorts shares are trading higher after the company announced it appointed a new CEO.</a>
&nbsp;
SPRO: 211% &#x7C; <a href="https://www.benzinga.com//node/45640097">Spero Therapeutics shares are trading higher after the company and GSK announced the Phase 3 study of tebipenem HBr met its primary endpoint and will stop early for efficacy.</a>

OKTA

Market-Moving News for May 28th

WIIM

Spero Therapeutics shares are trading higher after the company and GSK announced the Phase 3 study of tebipenem HBr met its primary endpoint and will stop early for efficacy.

Spero Therapeutics And GSK Announce The PIVOT-PO Phase 3 Study Of Tebipenem HBr Met Its Primary Endpoint And will Stop Early For Efficacy

Spero Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SPRO#NASDAQ">SPRO</a>) reported quarterly losses of $(0.25) per share which beat the analyst consensus estimate of $(0.55) by 54.55 percent. This is a 4.17 percent decrease over losses of $(0.24) per share from the same period last year. The company reported quarterly sales of $5.87 million which missed the analyst consensus estimate of $11.00 million by 46.60 percent. This is a 36.61 percent decrease over sales of $9.27 million the same period last year.

Earnings Beats

Earnings Misses

Spero Therapeutics Q1 EPS $(0.25) Beats $(0.55) Estimate, Sales $5.87M Miss $11.00M Estimate

Comments

Spero Therapeutics

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL